Alembic Pharmaceuticals Ltd

NSE: APLLTD · BSE: 533573 · Pharmaceuticals & Biotechnology · 80 announcements

Alembic Pharmaceuticals Ltd news stories on ALFA NewsRead the news →

Share price: ₹1,029.95
Market cap: ₹20,245 Cr
Revenue (annual): ₹7,345 Cr
Net profit (annual): ₹674.8 Cr
P/E (TTM): 24.0×Sector 43.8×
Promoter holding: 69.87%+0.00% QoQ
FII holding: 4.55%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

4 Nov 2026 14:40 IST BSE

PartnershipAlfa Alert

Alembic Pharmaceuticals Partnership

Alembic Pharmaceuticals expanded its strategic collaboration with DifGen Pharmaceuticals to commercialize over 20 complex generic products in the US. The portfolio targets a US$5 billion market.

From: DifGen Pharmaceuticals
Execution: Initial launches from FY28

Open announcement → Read the story on ALFA News Read the filing ↗

Alembic Pharmaceuticals Ltd by type

Management Change 13
Regulatory Approval 11
Debt & Borrowing 11
Merger & Restructuring 10
Earnings Call 6
Other Announcement 5
Business Update 5
Financial Results 4
Results Update 3
Board Meeting Date 3
Annual General Meeting 2
Credit Rating 2